Diabetes

Evidence suggests it improves outcomes and reduces hospitalizations.

The iLet Bionic Pancreas was associated with improved glycemic control and time in target glucose range compared to standard care in a cohort of people with type 1 diabetes aged 6-79 years of age.

Two new studies offer conflicting results.

A study provides insight into the real-world effects of 2.4 mg semaglutide (Wegovy) for weight management.

Modeling indicates a significant increase in patients with type 1 diabetes over the next several years.

The risk could allow unauthorized users to change insulin levels.

A survey offers new insight into patient preferences related to newer oral therapies in type 2 diabetes.

Research indicates that using an open-source automated insulin delivery systems can lead to greater glycemic control.

New research offers evidence that tirzepatide could help patients achieve glycemic goals.

Considering comorbidities is just as important as lowering patient HbA1c.

In the early stages of development, researchers find 2 treatments are efficacious for diabetes.

Software updates in closed-loop systems may lead to better time in range numbers for children with type 1 diabetes.

Timing of type 2 diabetes or hypertension diagnosis may impact the risk of primary open-angle glaucoma.

Improved glycemic control could reduce the risk of diabetes-related brain damage among teens and adolescents with type 1 diabetes.

New research indicates the medication has cardioprotective properties.

Using electronic medical record data from 2018-2020 obtained from 24 medical centers across the US, including Johns Hopkins, University of Colorado, and Mayo Clinic institutions, a new study suggests rates of youth onset type 2 diabetes increased 77% during the first year of the pandemic.

Used to treat a variety of concerns and found in many medicine cabinets, new research indicates that nonsteroidal anti-inflammatory drugs may pose a risk to patients with type 2 diabetes.

Clearance expands on initial clearance from January 2022.

Lack of blood clotting may afford some protection against common cardiovascular disease events, such as ischemic stroke.

The Inflation Reduction Act puts a $35 cap on monthly out-of-pocket expenses for insulin. The catch: It applies only to people covered by Medicare. The competition gearing up could drive down costs for others.

Overall numbers may be lower, but the obese, racial/ethnic minorities, and those without health care access have higher numbers of undiagnosed diabetes

Collaboration has been the name of the game in cardiometabolic care. Here's what's going on when managing patients who have type 2 diabetes and chronic kidney disease.

Studies tie disease to higher risk of COVID-related hospitalizations and deaths

Issues with a contract manufacturer have led to limited availability for semaglutide.

New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.